ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced endometrial cancer: three-drug combos tested in major trial
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New drug cocktail shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests two drug combinations (olaparib plus either vistusertib or capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can control tumor growth. About 159 partic…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
New hope for recurrent endometrial cancer: drug cocktails tested
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer growth enzymes or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the …
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination can shrink tumors or slow cancer growth. Part…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New combo therapy shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding an experimental drug (BMS-986205) to the immunotherapy nivolumab can shrink tumors or stop them from growing in people with endometrial cancer that has returned or persists. About 24 adults with certain types of endometrial cancer or carcinosarcoma…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
New drug combo targets recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase trial is testing two drugs, niraparib and copanlisib, together in people whose endometrial, ovarian, or related cancers have returned. The main goal is to find the safest dose and understand side effects. About 31 adults with specific cancer types are taking part…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC